VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2021 | Ongoing MDS clinical trials to look out for

Daniel Pollyea, MD, MS, University of Colorado, Denver, CO, comments on novel treatments targeting myelodysplastic syndromes (MDS) under development including pevonedistat, a NEDD8-activating enzyme (NAE) inhibitor, and sabatolimab, an anti-TIM-3 antibody. Dr Pollyea additionally highlights venetoclax and magrolimab, anti-CD47 monoclonal antibody, which are both undergoing clinical trials. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter